Vaxcyte, Inc. — Director's Dealing 2023

Jun 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2023-06-07

Reporting Person: Eydelman Mikhail (SVP, Gen Counsel & Corp Sec)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-07	Common Stock	F	645	$51.25	Disposed	21676	Direct

Footnotes

F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.

F2: Includes 539 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on May 17, 2023.